Coya Therapeutics has reported additional clinical data from an open-label study evaluating the safety and efficacy of low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease. The data shows a significant decrease in biomarker levels associated with neuroinflammation, supporting the initial positive results. The treatment also demonstrated biological activity by restoring peripheral Treg function and numbers and significantly lowering the blood levels of other proinflammatory cytokines and chemokines. An ongoing phase 2 trial is almost fully enrolled and should report top line results in July, 2024.